Anti-TN13B/ TNFSF13B/ BAFF monoclonal antibody

Anti-TN13B/ TNFSF13B/ BAFF antibody for FACS & in-vivo assay

Target products collectionGo to TNFSF13B/TNFSF13B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T02318-Ab-1/ GM-Tg-hg-T02318-Ab-2Anti-Human TNFSF13B monoclonal antibodyHuman
GM-Tg-rg-T02318-Ab-1/ GM-Tg-rg-T02318-Ab-2Anti-Rat TNFSF13B monoclonal antibodyRat
GM-Tg-mg-T02318-Ab-1/ GM-Tg-mg-T02318-Ab-2Anti-Mouse TNFSF13B monoclonal antibodyMouse
GM-Tg-cynog-T02318-Ab-1/ GM-Tg-cynog-T02318-Ab-2Anti-Cynomolgus/ Rhesus macaque TNFSF13B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T02318-Ab-1/ GM-Tg-felg-T02318-Ab-2Anti-Feline TNFSF13B monoclonal antibodyFeline
GM-Tg-cang-T02318-Ab-1/ GM-Tg-cang-T02318-Ab-2Anti-Canine TNFSF13B monoclonal antibodyCanine
GM-Tg-bovg-T02318-Ab-1/ GM-Tg-bovg-T02318-Ab-2Anti-Bovine TNFSF13B monoclonal antibodyBovine
GM-Tg-equg-T02318-Ab-1/ GM-Tg-equg-T02318-Ab-2Anti-Equine TNFSF13B monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T02318-Ab-1/ GM-Tg-hg-T02318-Ab-2; GM-Tg-rg-T02318-Ab-1/ GM-Tg-rg-T02318-Ab-2;
GM-Tg-mg-T02318-Ab-1/ GM-Tg-mg-T02318-Ab-2; GM-Tg-cynog-T02318-Ab-1/ GM-Tg-cynog-T02318-Ab-2;
GM-Tg-felg-T02318-Ab-1/ GM-Tg-felg-T02318-Ab-2; GM-Tg-cang-T02318-Ab-1/ GM-Tg-cang-T02318-Ab-2;
GM-Tg-bovg-T02318-Ab-1/ GM-Tg-bovg-T02318-Ab-2; GM-Tg-equg-T02318-Ab-1/ GM-Tg-equg-T02318-Ab-2
Products NameAnti-TNFSF13B monoclonal antibody
Formatmab
Target NameTNFSF13B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TNFSF13B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-1018Pre-Made Telitacicept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4
    BiosimilarGMP-Bios-ab-540Pre-Made Tabalumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody
    BiosimilarGMP-Bios-INN-767Pre-Made Briobacept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4
    BiosimilarGMP-Bios-ab-056Pre-Made Belimumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody
    BiosimilarGMP-Bios-ab-568Pre-Made Tibulizumab biosimilar, Bispecific Mixed mAb and scFv, Anti-TNFSF13B;IL17A/IL17 Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4;CTLA-8/CTLA8A therapeutic antibody
    BiosimilarGMP-Bios-INN-764Pre-Made Blisibimod Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4
    Target AntigenProducts DevelopingMulti-species TN13B/ TNFSF13B/ BAFF VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T02318-Ag-1tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B) protein
    ORF Viral VectorvGMLP002206human TNFSF13B Lentivirus particle
    ORF Viral VectorpGMLP002206human TNFSF13B Lentivirus plasmid
    ORF Viral VectorpGMLV000606house mouse Tnfsf13b Lentivirus plasmid
    ORF Viral VectorpGMLPm000459mouse Tnfsf13b Lentivirus plasmid
    ORF Viral VectorvGMLV000606house mouse Tnfsf13b Lentivirus particle
    ORF Viral VectorvGMLPm000459mouse Tnfsf13b Lentivirus particle


    Target information

    Target IDGM-T02318
    Target NameTNFSF13B
    Gene ID10673,24099,498666,693917,485545,101088640,504507,100051550
    Gene Symbol and SynonymsBAFF,BLYS,CD257,D8Ertd387e,DTL,RGD1561519,TALL-1,TALL1,THANK,TNFSF13B,TNFSF20,TNLG7A,ZTNF4
    Uniprot AccessionQ9Y275
    Uniprot Entry NameTN13B_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index, Cytokine Target
    DiseaseLupus Glomerulonephritis
    Gene EnsemblENSG00000102524
    Target ClassificationN/A

    The target: TNFSF13B, gene name: TNFSF13B, also named as BAFF, BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4. The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.